Cochrane · systematic review · CD001951
Haloperidol dose for the acute phase of schizophrenia
Donnelly, L, Rathbone, J, Adams, CE · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 7 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
STANDARD LOWER DOSE (> 3 to 7.5 mg/day) versus OTHER DOSES for the acute phase of schizophrenia
Population: people with the acute phase of schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES | RR 0.12 [0.01, 2.12] | 2 studies · 64 participants | Very low Downgraded: risk of bias |
Leaving the study early (2‐10 weeks) vs. high dose (> 15‐35 mg/day) STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES | RR 0.78 [0.47, 1.28] | 4 studies · 191 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES | RR 1.09 [0.67, 1.75] | 1 study · 48 participants | Very low Downgraded: risk of bias |
Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. high dose (> 15‐35 mg/day) STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES | RR 0.95 [0.75, 1.19] | 2 studies · 81 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES | RR 0.12 [0.01, 2.12] | 2 studies · 64 participants | Very low Downgraded: risk of bias |
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (> 15‐35 mg/day) STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES | RR 0.59 [0.45, 0.78] | 3 studies · 144 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Mental state/behaviour: clinically significant agitation (2‐10 weeks) STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES | RR 0.93 [0.69, 1.26] | 1 study · 65 participants | Very low Downgraded: risk of bias |